4basebio (LON:4BB) Shares Up 4.8% – Here’s What Happened

4basebio PLC (LON:4BB)’s stock price rose 4.8% during trading on Wednesday . The stock traded as high as GBX 496.80 and last traded at GBX 496.80. Approximately 242 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 1,596 shares. The stock had previously closed at GBX 474.

4basebio Stock Performance

The stock has a 50 day simple moving average of GBX 541.52 and a 200 day simple moving average of GBX 645.70. The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47. The company has a market cap of £76.93 million, a price-to-earnings ratio of -5.02 and a beta of 1.09.

Insider Activity at 4basebio

In related news, insider Amy Walker purchased 2,650 shares of the firm’s stock in a transaction on Friday, February 13th. The stock was purchased at an average price of GBX 586 per share, for a total transaction of £15,529. Also, insider Heikki Lanckriet acquired 3,000 shares of the stock in a transaction on Tuesday, February 10th. The stock was purchased at an average cost of GBX 576 per share, with a total value of £17,280. In the last ninety days, insiders have purchased 6,650 shares of company stock worth $3,865,900. 12.07% of the stock is currently owned by company insiders.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.